Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Newinvestor68, losingmyshirt you should find another hobby

<< Previous

Bullboard Posts

Next >>

Comment by Newinvestor68on Jul 28, 2020 10:32am

140 Views

Post# 31330266

RE:Newinvestor68, losingmyshirt you should find another hobby

Not a shorter at all and I want Kaly to do well. Believe me I love money and do not have enough knowledge to even consider shorting.

I have read all of this and the outcome on the rats is exciting. What I don't like is that the only people talking about it is Kaly. No other trials, no additional funding, no FDA testing and they couldn't raise all the money they were after.

Those are facts that can't be ignored

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo